An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Senseonics Holdings, Inc. (NYSE American: SENS) is set to release its first quarter 2024 financial results on May 13, 2024, after the market closes. The company specializes in the development of long-term, implantable continuous glucose monitoring systems for individuals with diabetes. A conference call to discuss the performance is scheduled for 4:30 p.m. (Eastern Time) on the same day.
Senseonics Holdings, Inc. (NYSE American: SENS) prevede di rilasciare i risultati finanziari del primo trimestre del 2024 il 13 maggio 2024, dopo la chiusura del mercato. L'azienda è specializzata nello sviluppo di sistemi di monitoraggio continuo del glucosio impiantabili a lungo termine per individui con diabete. È prevista una teleconferenza per discutere le performance lo stesso giorno alle 16:30 (orario della costa orientale).
Senseonics Holdings, Inc. (NYSE American: SENS) tiene previsto publicar los resultados financieros del primer trimestre de 2024 el 13 de mayo de 2024, después del cierre del mercado. La compañía se especializa en el desarrollo de sistemas de monitoreo continuo de glucosa implantables y de larga duración para personas con diabetes. Se ha programado una llamada de conferencia para discutir el rendimiento ese mismo día a las 4:30 p.m. (hora del Este).
센센스홀딩스(Senseonics Holdings, Inc., 미국 뉴욕 증권거래소: SENS)는 2024년 5월 13일, 시장 마감 후에 2024년 1분기 재무 결과를 발표할 예정입니다. 이 회사는 당뇨병 환자를 위한 장기 이식형 연속 혈당 모니터링 시스템 개발을 전문으로 합니다. 그 날 같은 날 오후 4시 30분 (동부 시간)에 성과에 대해 논의하기 위한 컨퍼런스 콜이 예정되어 있습니다.
Senseonics Holdings, Inc. (NYSE American : SENS) prévoit de publier ses résultats financiers pour le premier trimestre de 2024 le 13 mai 2024, après la fermeture du marché. L'entreprise est spécialisée dans le développement de systèmes de surveillance continue du glucose implantables et à long terme pour les personnes diabétiques. Une conférence téléphonique pour discuter des performances est programmée à 16 h 30 (heure de l'Est) le même jour.
Senseonics Holdings, Inc. (NYSE American: SENS) plant, seine Finanzergebnisse für das erste Quartal 2024 am 13. Mai 2024 nach Börsenschluss zu veröffentlichen. Das Unternehmen ist spezialisiert auf die Entwicklung von langfristigen, implantierbaren kontinuierlichen Glukoseüberwachungssystemen für Menschen mit Diabetes. Ein Konferenzanruf zur Besprechung der Ergebnisse ist für den gleichen Tag um 16:30 Uhr (Ostzeit) angesetzt.
Positive
None.
Negative
None.
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2024 financial results after market close on Monday, May 13, 2024.
Management will hold a conference call to review the Company’s first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 7182212, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
When will Senseonics Holdings, Inc. release its first quarter 2024 financial results?
Senseonics Holdings, Inc. will release its first quarter 2024 financial results after market close on Monday, May 13, 2024.
What is the focus of Senseonics Holdings, Inc.?
Senseonics Holdings, Inc. specializes in the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes.
What time is the conference call to review the Company’s first quarter 2024 performance?
The conference call to discuss Senseonics Holdings, Inc.'s first quarter 2024 performance will start at 4:30 p.m. (Eastern Time) on May 13, 2024.
How can one listen to the conference call?
To listen to the conference call, dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International) with the passcode 7182212, approximately ten to five minutes prior to the start time.
Where can the webcast of the conference call be accessed?
The webcast of the conference call will be available on Senseonics Holdings, Inc.'s website at www.senseonics.com under 'Investor Relations,' then 'Events & Publications,' and will be archived for future reference.
